Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COR

DatePrice TargetRatingAnalyst
12/4/2024$280.00Outperform
Mizuho
9/18/2024$275.00 → $245.00Buy → Neutral
BofA Securities
2/26/2024$261.00Outperform
Leerink Partners
1/3/2024$242.00Overweight
Barclays
12/14/2023$213.00Equal Weight
Wells Fargo
12/14/2021$162.00 → $170.00Buy → Neutral
Citigroup
11/26/2021$136.00 → $170.00Sector Perform
RBC Capital
11/16/2021Underweight → Equal-Weight
Barclays
More analyst ratings

$COR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

    $COR
    Other Pharmaceuticals
    Health Care
  • Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

    Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. The sale of Cencora shares by Walgreens Boots Alliance is occurring simultaneously with the early set

    $COR
    Other Pharmaceuticals
    Health Care
  • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

    Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

    $COR
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$COR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$COR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$COR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$COR
SEC Filings

See more

$COR
Leadership Updates

Live Leadership Updates

See more
  • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    $COR
    Other Pharmaceuticals
    Health Care
  • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    $AXS
    $COR
    $POR
    $WTT
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

$COR
Financials

Live finance-specific insights

See more
  • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

    $COR
    Other Pharmaceuticals
    Health Care
  • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

    Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

    $COR
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • Cencora Reports Fiscal 2025 First Quarter Results

    Revenue of $81.5 billion for the First Quarter, a 12.8 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.50 and Adjusted Diluted EPS of $3.73 Adjusted Diluted EPS Guidance Range Raised to $15.25 to $15.55 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items descri

    $COR
    Other Pharmaceuticals
    Health Care

$COR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more